Study authors Dr. John Lee and Dr. Galina Semenova.
Photo Credit: Courtesy of UCLA Health
Scientific Frontline: Extended "At a Glance" Summary: Enhancing Antibody-Drug Conjugates for Prostate Cancer
The Core Concept: A novel therapeutic approach enhances the efficacy of antibody-drug conjugates (ADCs) by pairing them with a compound that blocks BCL-XL, a cancer cell survival protein, rendering metastatic castration-resistant prostate cancer cells more vulnerable to treatment.
Key Distinction/Mechanism: Instead of designing an entirely new therapy, this strategy improves existing ADCs by combining DNA-damaging chemotherapy payloads with a BCL-XL inhibitor. This dual approach strips cancer cells of their ability to activate protective pathways and survive significant DNA damage, triggering substantially more programmed cell death than either treatment alone.
Major Frameworks/Components:
- Antibody-Drug Conjugates (ADCs): Precision medicines utilizing an antibody to deliver potent chemotherapy payloads directly to cancer cells via a molecular linker.
- Simultaneous Multi-Targeting: Exploiting the simultaneous presence of three specific proteins (B7-H3, PSMA, and STEAP1) frequently found on the same prostate cancer cells to increase therapeutic reach while sparing healthy tissue.
- BCL-XL Inhibition: Blocking a specific protein pathway that cancer cells rely upon to prevent programmed cell death following DNA damage.
- TP53 Dependence: Relying on an intact TP53 tumor suppressor gene, which correlates with a particularly strong biological response to the combined therapy.
Branch of Science: Molecular Oncology, Pharmacology, and Urology.
Future Application: This research provides a foundational framework for engineering next-generation ADCs, tailoring precision medicines to individual tumor biology, and utilizing genetic testing to identify patients most likely to benefit from specific targeted therapy combinations.
Why It Matters: Metastatic castration-resistant prostate cancer is an aggressive disease that currently remains incurable and typically stops responding to standard hormone therapy. This combinatorial strategy addresses the significant barrier of treatment resistance, offering a highly precise path forward for long-term disease control.
UCLA researchers have identified a promising strategy to make a new class of targeted cancer therapies more effective against one of the deadliest forms of prostate cancer, potentially overcoming treatment resistance that has limited their success.
Metastatic castration-resistant prostate cancer, an aggressive form of the disease that no longer responds to hormone therapy, remains incurable despite advances in treatment. Antibody-drug conjugates (ADCs), precision medicines that deliver potent cancer-killing drugs directly to tumors, have transformed care for several cancers but have shown only modest and often short-lived benefits in prostate cancer.
But new research, led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center and published in the Journal of Clinical Investigation, shows that combining ADCs with a drug that blocks a cancer cell survival protein called BCL-XL can make prostate cancer cells more susceptible to treatment. In laboratory and animal models, the combination triggered greater cancer cell death and slowed tumor growth compared with either therapy alone, suggesting a potential new approach for developing the next generation of targeted therapies for advanced prostate cancer.
"Our findings show that these therapies offer tremendous engineering flexibility," said Dr. John Lee, associate professor-in-residence in the Division of Hematology/Oncology at the David Geffen School of Medicine at UCLA and co-senior author of the study. "Rather than introducing a single new therapy, we've established a framework for building more effective antibody-drug conjugates by pairing complementary drug payloads and targeting multiple proteins on prostate cancer cells. That flexibility gives us an opportunity to better tailor these therapies to the biology of advanced prostate cancer."
Antibody-drug conjugates have emerged as one of the most promising advances in precision oncology because they are designed to deliver potent chemotherapy directly to cancer cells while limiting damage to healthy tissue. Several ADCs have become standard treatments for breast, bladder, and blood cancers, but they have not produced the same durable responses in metastatic prostate cancer.
Researchers have long hoped ADCs would change that. An ADC combines an antibody that recognizes a protein on cancer cells with a potent chemotherapy payload connected by a molecular linker that releases the drug once it reaches the tumor.
"It's essentially a way of delivering chemotherapy with much greater precision," said Lee, who is an investigator in the UCLA Health Jonsson Comprehensive Cancer Center and at the UCLA Broad Stem Cell Research Center.
Several ADCs have become standard treatments for other cancers. But in prostate cancer, clinical trials have produced only modest and often short-lived responses.
To address this issue, rather than designing a completely new therapy, Lee and his team looked for ways to improve existing ADCs.
The researchers first analyzed tumor samples from patients with advanced prostate cancer and found that three proteins commonly targeted by ADCs—B7-H3, PSMA, and STEAP1—are frequently found on the same cancer cells. That finding suggests multiple ADCs could potentially target the same tumor simultaneously, increasing the number of cancer cells reached while limiting exposure to healthy tissues.
The researchers then tested dozens of combinations of drugs commonly used as ADC payloads, looking for combinations that worked better together than expected. One combination consistently outperformed the others: DNA-damaging drugs paired with a compound that blocks BCL-XL, a protein cancer cells use to prevent programmed cell death.
Normally, cancer cells can survive significant DNA damage by activating protective pathways. Blocking BCL-XL removes one of those escape routes, making it much more difficult for damaged tumor cells to recover.
In prostate cancer cells grown in the laboratory, the combination triggered substantially more cell death than either treatment alone. Similar results were seen in mice with advanced prostate tumors, where the combination slowed tumor growth significantly more than either therapy by itself.
The researchers also found that tumors with an intact version of the TP53 tumor suppressor gene responded particularly well, suggesting genetic testing could eventually help identify patients most likely to benefit.
"We were surprised by how many unexpected payload combinations showed synergy," Lee said. "We're now engineering next-generation ADCs that incorporate these findings and testing additional combinations that could further improve treatment."
If the findings are confirmed in future clinical trials, the approach could offer a new strategy for improving antibody-drug conjugates against metastatic prostate cancer, where treatment resistance remains one of the greatest barriers to long-term disease control.
Published in journal: Journal of Clinical Investigation
Authors: Galina Semenova, Sander B. Frank, Ruth Dumpit, Wanting Han, Ilsa Coleman, Roman Gulati, Canan D. Dirican, Tarana Arman, Jessica Maruwan, Colm Morrissey, Michael C. Haffner, Peter S. Nelson, and John K. Lee
Source/Credit: University of California, Los Angeles / Health | Denise Heady
Edited by: Scientific Frontline
Reference Number: ongy080326_01
